- Licensing in-out/Contract
- Contact us
The growth plan of Laboratorios ERN, both at national and international level is currently one of its principle priorities, the licensing in –licensing out department being responsible for negotiating strategic agreements which allow this objective to be reached.
These agreements are fundamentally based on:
Recent acquisitions of assets have been:
Metalgial: the first and only metamizole in drops for pediatric administration in Spain.
Apirofeno: The first paediatric ibuprofen in Spain which is administered with a graduated syringe according to the child’s weight, in order to avoid the risk of over or under dosage.
From 1996 Laboratorios ERN has actively looked for agreements with a variety of companies for the promotion of products which, according to their profile adapt perfectly to the target of doctors with who the laboratory works, especially paediatrics and primary care. Results clearly demonstrate our promotional capability for third parties.
Examples of these agreements are:
An example of licensing out is Apiretal:
Currently there is a European project with the objective of realising the European expansion of Apiretal® with a new register of pharmaceutical specialisation under the European brand APIREDOL in various states that are involved: France, Germany, Italy, Portugal, Poland, Czech Republic and Slovakia. For this it has prepared the documentation in CTD format, actualised according to the latest European directives and guidelines. Currently it is being commercialised in Poland under the brand name Pedicetamol.